Spero's TB program first licensing deal for Gates Medical Research Institute

A partnership to develop Spero's Phase I compound for tuberculosis is the first licensing deal announced by Gates MRI, the translational research institute launched by the Bill & Melinda Gates Foundation in 2017.

Spero Therapeutics Inc. (NASDAQ:SPRO) granted The Bill & Melinda Gates Medical Research Institute (Cambridge, Mass.) an exclusive license to develop, manufacture and commercialize SPR720 for tuberculosis infection in low- and middle-income countries (LMIC)...